





[illegible]



FOETAO" E2TFE860








FIG. 5A




FIG. 5B

09831123-001301

6/17




FIG. 6

7/17

FIG. 7A






FIG. 7B



8/17

FIG. 8



- ▨ HOOH oxidized HSA containing 27.9 pmol cysteic acid/μg protein
- ▩ HOOH oxidized HSA containing 11.7 pmol cysteic acid/μg protein
- ▤ HOOH oxidized HSA containing 4.0 pmol cysteic acid/μg protein
- Unoxidized HSA






FIG. 9A





FIG. 9B

09831123-081301

Figure 10

Reactivity of mAb against PAoxBSA and unoxidized BSA



Vmax Points = 61

Well	○ F1	□ F2	△ F3	◇ F4	● H1	■ H2	▲ H3	◆ H4
Vmax	1.371	1.259	1.091	1.217	749.71	641.43	715.77	741.14
R <sup>2</sup>	0.950	0.944	0.912	0.929	0.983	0.974	0.994	0.990

Wells coated with either 1 µg of PAoxBSA or 1 µg of unoxidized BSA.


11/17

09/831123

**Figure 11**  
**Plate A - 96-well template**

	1	2	3	4	5	6	7	8	9	10	11	12
A	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1µg K2.F1.3	PAox K2.F1.3	OVA + K2.F1.3	GSA K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6
B	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1 K2.F1.3	µg PA K2.F1.3	ox OVA K2.F1.3	K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6
C	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.3	1µg C K2.F1.3	M-OVA K2.F1.3	K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6
D	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.3	1µg K2.F1.3	OVA K2.F1.3	K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6
E	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1µg K2.F1.3	OVA K2.F1.3	-oxCAP K2.F1.3	37 K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6
F	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1µg K2.F1.3	OVA-u K2.F1.3	noxCA K2.F1.3	P 37 K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6
G	1 K2.A12	µg PA K2.A12	ox OV K2.A12	A K2.A12	1µg K2.A12	OVA- K2.A12	oxCAP K2.A12	37 K2.A12	K2.A12	K2.A12	K2.A12	K2.A12
H	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1µg K2.F1.3	PAox K2.F1.3	OVA + K2.F1.3	CA K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6

12/17






Figure 13 - Patient Sera (1/1000)






FIG. 14

ELISA of Patient Sera (1:200) on PAoxOVA in the absence (col 1) and presence of oxOVA (col 2). Percent Inhibition uncorrected for the blank.



FOETAO" E2TFE860

Figure 15 - Bailey Renal Patients Plasma 1:200








Figure 16A




Figure 16B